CEL-SCI Pushes Multikine to Confirmatory Study After Strong Phase III Data

Ticker: CVM · Form: 10-K · Filed: Dec 29, 2025 · CIK: 725363

Sentiment: mixed

Topics: Biotechnology, Immunotherapy, Cancer Treatment, Clinical Trials, Head and Neck Cancer, FDA Approval, Oncology

Related Tickers: CVM, MRK, BMY

TL;DR

**CVM is a high-risk, high-reward bet on Multikine's confirmatory trial, with promising Phase III data suggesting a significant survival advantage in a niche head and neck cancer population.**

AI Summary

CEL-SCI Corporation, a late clinical-stage biotechnology company, reported no revenue for the fiscal year ended September 30, 2025, as its lead product candidate, Multikine, remains investigational. The company is focused on developing Multikine for head and neck cancers and LEAPS technology for rheumatoid arthritis. Key business changes include the FDA's indication in May 2024 for CEL-SCI to proceed with a 212-patient confirmatory registration study for Multikine in a specific target population of newly diagnosed advanced primary head and neck cancer patients. Multikine's Phase III study showed a 73% survival rate versus 45% for control at 5 years in the target population, with a hazard ratio of 0.35. Risks include the inherent uncertainties of clinical trials, regulatory approvals, and the ability to secure sufficient funding to continue as a going concern. The strategic outlook centers on gaining regulatory approval for Multikine, which targets a global market of approximately 100,000 patients annually, and potentially entering the cancer immunotherapy market, projected to reach $196.45 billion by 2030.

Why It Matters

CEL-SCI's progress with Multikine could significantly impact the treatment landscape for head and neck cancer, particularly for patients with low PD-L1 expression who may not benefit from existing immunotherapies like Keytruda. For investors, successful regulatory approval would unlock a new market segment, potentially disrupting established players like Merck and Bristol Myers Squibb. Employees and customers could see a novel, pre-surgical treatment option that has shown a 73% 5-year survival rate in its target population, offering a substantial improvement over the 45% for standard of care. The broader market could witness a shift in cancer immunotherapy strategies, emphasizing early intervention.

Risk Assessment

Risk Level: high — CEL-SCI is a late clinical-stage biotechnology company with no approved products and no revenue, indicating a high reliance on future product success. The company explicitly lists 'our ability to continue as a going concern' and 'our liquidity' as significant risks, highlighting financial instability. Furthermore, the success of Multikine hinges on a confirmatory registration study and subsequent regulatory approvals, which are inherently uncertain and costly processes.

Analyst Insight

Investors should approach CVM with extreme caution, recognizing its speculative nature as a clinical-stage biotech. While the Phase III data for Multikine is compelling, the stock's future is entirely dependent on successful completion of the confirmatory study and FDA approval. Consider a small, speculative position only if you have a high-risk tolerance and believe in the long-term potential of Multikine's unique pre-surgical approach.

Financial Highlights

debt To Equity
Not Disclosed
revenue
$0
operating Margin
Not Disclosed
total Assets
Not Disclosed
total Debt
Not Disclosed
net Income
Not Disclosed
eps
Not Disclosed
gross Margin
Not Disclosed
cash Position
Not Disclosed
revenue Growth
N/A

Revenue Breakdown

SegmentRevenueGrowth
Product Sales$0N/A

Key Numbers

Key Players & Entities

FAQ

What is CEL-SCI Corporation's primary product candidate?

CEL-SCI Corporation's primary product candidate is Multikine (Leukocyte Interleukin, Injection), an investigational Phase 3 immunotherapy for the potential treatment of certain head and neck cancers.

What were the key survival results for Multikine in its Phase III clinical trial?

In the target patient population, Multikine demonstrated a 73% survival rate at 5 years after treatment, compared to only 45% for the control group. The hazard ratio was 0.35, indicating a significant reduction in the risk of death.

Has the FDA approved Multikine for sale?

No, none of CEL-SCI's product candidates, including Multikine, have been approved for sale by the FDA or any other regulatory agency. The safety or efficacy of these products has not yet been established for any human use.

What is the target patient population for Multikine?

Multikine targets newly diagnosed adult patients with resectable locally advanced primary squamous cell carcinoma of the head and neck (SCCHN) in the oral cavity, who have no lymph node involvement (via PET imaging) and low PD-L1 tumor expression (TPS < 10) (via biopsy).

How does Multikine differentiate itself from other immunotherapies like Keytruda?

Multikine is unique because it is given first, right after diagnosis and before any other treatment, and it targets patients with low PD-L1 tumor expression. In contrast, checkpoint inhibitors like Keytruda appear to work best for patients with high PD-L1 expression.

What is the status of CEL-SCI's confirmatory registration study for Multikine?

In May 2024, the FDA indicated that CEL-SCI may move forward with a 212-patient randomized controlled confirmatory registration study of Multikine in the target population.

What are the financial risks associated with investing in CEL-SCI Corporation?

CEL-SCI is a non-revenue generating company with no approved products, making it highly dependent on successful clinical development and regulatory approval. The company explicitly identifies its ability to continue as a going concern and its liquidity as significant risks.

What is the estimated global market size for cancer immunotherapy?

A Bloomberg report from January 2023 asserted that the global cancer immunotherapy market is expected to reach USD $196.45 billion by 2030, growing at a CAGR of 7.2% during the forecast period.

Did Multikine show any significant safety issues in its clinical trials?

No demonstrable safety signals or toxicities were observed in approximately 740 Multikine-treated subjects across multiple clinical trials. Adverse event and serious adverse event incidences were not significantly different between treatment and control groups.

What is the significance of 'pre-surgical responses' for Multikine?

CEL-SCI observed statistically significant pre-surgical reductions (30% or more tumor size reduction) and downstages (disease improvement) after Multikine treatment. The Phase III trial demonstrated that patients with these pre-surgical responses lived longer, with PSR patients having a 72% 5-year survival rate.

Risk Factors

Industry Context

CEL-SCI operates in the rapidly expanding cancer immunotherapy market, which is projected to reach $196.45 billion by 2030 with a 7.2% CAGR. This sector is characterized by targeted therapies that leverage the patient's immune system. Key trends include increasing regulatory approvals for novel treatments and a shift towards immunotherapies over traditional options due to their targeted action.

Regulatory Implications

The company faces significant regulatory hurdles, primarily centered on obtaining FDA approval for Multikine. The indication to proceed with a 212-patient confirmatory study is a positive step, but success is contingent on demonstrating statistically significant survival benefits in the target population. Any delays or failures in clinical trials or regulatory submissions pose a major risk.

What Investors Should Do

  1. Monitor Regulatory Filings and Updates
  2. Assess Funding Needs and Sources
  3. Analyze Phase III Data Deeply
  4. Evaluate Market Penetration Strategy

Key Dates

Glossary

Multikine
CEL-SCI's investigational immunotherapy drug candidate, Leukocyte Interleukin, Injection, intended for the treatment of certain head and neck cancers. (It is the company's lead product candidate and the primary focus of its development efforts and future revenue potential.)
LEAPS technology
Ligand Epitope Antigen Presentation System, a technology platform developed by CEL-SCI for potential treatment of diseases like rheumatoid arthritis. (Represents a secondary development area for the company, diversifying its research beyond cancer immunotherapy.)
Investigational Therapy
A drug or treatment that is still undergoing clinical trials and has not yet received approval from regulatory authorities like the FDA for general use. (Highlights that Multikine's safety and efficacy are not yet established for commercial sale, and its approval is uncertain.)
Confirmatory Registration Study
A type of clinical trial designed to confirm the efficacy and safety of a drug candidate, often required by regulatory agencies like the FDA before granting marketing approval. (The FDA's indication to proceed with such a study for Multikine is a crucial step in the regulatory approval process.)
Hazard Ratio
A measure used in survival analysis to compare the hazard rate of one treatment group to another. A ratio less than 1 indicates a reduced risk of the event (e.g., death) in the treatment group. (The reported hazard ratio of 0.35 for Multikine in the Phase III study indicates a significantly lower risk of death in the treated group compared to the control.)
Going Concern
An accounting assumption that a company will continue to operate for the foreseeable future. If there is substantial doubt, it must be disclosed. (The company's financial situation raises substantial doubt about its ability to continue as a going concern, indicating significant financial risk.)
Cancer Immunotherapy
A type of cancer treatment that harnesses the patient's own immune system to fight cancer cells. (This is the market segment CEL-SCI aims to enter with Multikine, a market projected to be worth $196.45 billion by 2030.)

Year-Over-Year Comparison

As the company reported no revenue in the prior fiscal year ended September 30, 2024, revenue remains at $0, with no revenue growth. Net income, EPS, margins, and debt-to-equity ratios are not detailed in the provided text for comparison. However, the key development is the FDA's indication in May 2024 to proceed with a confirmatory registration study, representing significant progress in the regulatory pathway compared to the previous period.

Filing Stats: 4,527 words · 18 min read · ~15 pages · Grade level 13.5 · Accepted 2025-12-23 17:36:36

Key Financial Figures

Filing Documents

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS This report contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. You can generally identify these forward-looking statements by forward-looking words such as "anticipates," "believes," "expects," "intends," "future," "could," "estimates," "plans," "would," "should," "potential," "continues" and similar words or expressions (as well as other words or expressions referencing future events, conditions or circumstances). These forward-looking statements involve risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements, including, but not limited to: the progress and timing of, and the amount of expenses associated with, our research, development and commercialization activities for our product candidates, including Multikine; our expectations regarding the timing, costs and outcome of any pending or future litigation matters, lawsuits or arbitration proceedings; the success of our clinical studies for our product candidates; our ability to obtain U.S. and foreign regulatory approval for our product candidates and the ability of our product candidates to meet existing or future regulatory standards; our expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits and effectiveness of our product candidates; the safety profile and related adverse events of our product candidates; our ability to manufacture sufficient amounts of Multikine or our other product candidates for use in our clinical studies or, if approved, for commercialization activities following such regulatory approvals; our plans with respect to collaborat

BUSINESS

ITEM 1. BUSINESS CEL-SCI's PRODUCT CANDIDATES CEL-SCI Corporation is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. CEL-SCI is currently focused on the development of the following product candidates and technologies with an emphasis on Multikine: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; and 2) L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology, or LEAPS, with several product candidates under development for the potential treatment of rheumatoid arthritis. Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in this report as Multikine. Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review under CEL-SCI's future anticipated regulatory submission for approval. None of CEL-SCI's product candidates have been approved for sale, barter or exchange by the Food and Drug Administration (FDA) or any other regulatory agency for any use to treat disease in humans nor has the safety or efficacy of these products been established for any use. There can be no assurance that obtaining marketing approval from the FDA in the United States and by comparable agencies in most foreign countries will be granted. MULTIKINE, THE PHASE III CLINICAL TRIAL RESULTS, AND PATH FORWARD Immunotherapy is a large, high growth market. Immunotherapies use the patient's own immune system to fight disease. These "targeted therapies" are at the forefront of modern cancer research. A Bloomberg report from January 2023 asserted that: The global cancer immunotherapy market is expected to reach USD $196.45 billion by 2030, registering CAGR of 7.2% during the foreca

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing